Detailed analysis of tumor subtypes identified CRPC and prostate neuroendocrine carcinoma as the tumors with the highest amplification rate (12–23%) of EZH2, SUZ12 and EED genes. Here, EZH2 is linked to prostate neuroendocrine neoplasm.